摘要
目的探讨同步放化疗治疗不能手术的食管癌的近期疗效、生存期及毒性反应。方法88例食管癌患者根据入选标准随机分组,43例进入放疗+化疗组(放化组),45例进入单纯放疗组(单放组)。化疗为第1～4天氟尿嘧啶500mg/m2+顺铂20mg/m2(DF方案)。放疗从第1天即开始,6MVX线三野等中心照射,DT60～65Gy,30～33分次,6.0～6.5周。结果放化组与单放组完全缓解率分别为32.6%、13%(χ2=4.63,P<0.05)。1、2、3年局部控制率放化组分别为79%、65%、51%,单放组的分别为69%、49%、42%(χ2=3.12,P=0.056)。1、2、3年生存率放化组分别为77%、58%、47%,单放组的分别为67%、42%、38%(χ2=2.27,P=0.132)。放化组毒性反应大于单放组,但患者均能耐受。结论以DF方案化疗配合放疗不能手术的食管癌近期疗效和局部控制率较好,有提高远期生存率可能,虽毒性反应增加但能耐受。
Objective Objective To evaluate the response, survival and toxicity of concurrent chemoradiotherapy for patients with inoperable esophageal cancer. Methods Eighty-eight patients with inoperable esophageal cancer were divided randomly into two groups, 43 patients in group R ＋ C received chemoradiotherapy, while 45 patients in group R received radiotherapy only. For both groups, the same radiation technic was carried out by conventional fractionafion, to a total dose of 60-65 Gy/30-33Fr/6.0-6.5 W. For group R ＋ C patients, concurrent chemotherapy（5-Fu 500 mg/d1-4, DDP 20 mg/d1-4） was given. Results Complete response rate in group R ＋ C was 33%, while in group R, it was 13% （ P 〈 0.05）. The 1-, 2- and 3-year local control rate in group R ＋ C was 79 %, 65 % and 51%, while in group R, it was 69 %, 49 % and 42 % respectively; The 1-, 2- and 3-year survive rate in group R＋ C was77% ,58% and 47% ,while in group R, it was 67%, 42% and 38% （X^2=2.27,P=0.132） respectively. The acute toxic effect was severer in group R ＋ C than in group R. Conclusions Concurrent chemoradiotherapy, being able to improve the complete response rate, may have the potential of improving the survival rate of iroperable esophageal cancer, but it can also increase the acute toxic effect.
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2006年第3期185-187,共3页
Chinese Journal of Radiation Oncology
关键词
食管肿瘤/放射疗法
食管肿瘤/化学疗法
预后
Esophageal neoplasmas/radiotherapy
Esophageal neoplasmas/chemotherapy
Prognosis
